Abstract

While patient groups at risk for severe COVID-19 infections are now well identified, the risk factors associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission and immunization are still poorly understood. In a cohort of staff members of a Belgian tertiary academic hospital tested for SARS-CoV-2 antibodies during the early phase of the pandemic and followed-up after 6 weeks, 3 months and 10 months, we collected personal, occupational and medical data, as well as symptoms based on which we constructed a COVID-19 score. Seroprevalence was higher among participants in contact with patients or with COVID-19 confirmed subjects or, to a lesser extent, among those handling respiratory specimens, as well as among participants reporting an immunodeficiency or a previous or active hematological malignancy, and correlated with several symptoms. In multivariate analysis, variables associated with seropositivity were: contact with COVID-19 patients, immunodeficiency, previous or active hematological malignancy, anosmia, cough, nasal symptoms, myalgia, and fever. At 10 months, participants in contact with patients and those with higher initial COVID-19 scores were more likely to have sustained antibodies, whereas those with solid tumors or taking chronic medications were at higher risk to become seronegative.

Details

Title
Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers
Author
Grégoire, Céline 1 ; Huynen, Pascale 2 ; Gofflot, Stéphanie 3 ; Seidel, Laurence 4 ; Maes, Nathalie 4 ; Vranken, Laura 5 ; Delcour, Sandra 5 ; Moutschen, Michel 6 ; Hayette, Marie-Pierre 2 ; Kolh, Philippe 7 ; Melin, Pierrette 2 ; Beguin, Yves 8 

 CHU Sart-Tilman, Division of Hematology, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
 CHU of Liège, Division of Medical Microbiology, Unilab, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, Center for Interdisciplinary Research On Medicines, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 CHU of Liège, Biothèque Hospitalo-Universitaire de Liège (BHUL), Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
 CHU of Liège, Department of Biostatistics and Medico-Economic Information, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
 CHU of Liège, Unilab, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
 CHU of Liège, Division of Infectious Diseases and General Internal Medicine, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, GIGA-I3 Laboratory of Immunology, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 CHU of Liège, Department of Information System Management, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, Department of Biomedical and Preclinical Sciences, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
 CHU Sart-Tilman, Division of Hematology, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); CHU of Liège, Biothèque Hospitalo-Universitaire de Liège (BHUL), Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, GIGA-I3 Laboratory of Hematology, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2675834251
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.